Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05500170 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Benefits of Nicotinamide Riboside Upon Cognition and Sleep

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: details revised at 1 of 1 entry
    • Publications: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 2 words
  2. Re-verified, no change to tracked fieldsv6
  3. Primary completion date: Mar 30, 2024 to Aug 30, 2027
    • Study completion date: Aug 30, 2024 to Aug 30, 2027
    v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 2 to 3
    • Start date changed from estimate of May 1, 2023 to Apr 4, 2023
    v4
  5. Start date: Dec 30, 2022 to May 1, 2023v3
  6. Start date: Nov 30, 2022 to Dec 30, 2022
    • Primary completion date: Nov 30, 2024 to Mar 30, 2024
    • Study completion date: Jan 30, 2025 to Aug 30, 2024
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Poor sleep quality and short sleep duration may be a mechanistic component of cognitive impairment in older adults, associated with a decline in brain-derived neurotrophic factor. Increasing the availability of nicotinamide adenine dinucleotide (NAD+) with supplementation of its precursor, nicotinamide riboside (NR), a form of vitamin B3 may increase the expression of brain-derived neurotrophic factor. This study proposes to examine the benefits of NR supplementation on sleep and cognitive function in older adults with comprehensive subjective and objective measures and to explore its impacts on serum brain-derived neurotrophic factor.
Trial Details
NCT Number NCT05500170
Lead Sponsor State University of New York at Buffalo
Conditions
(from sponsor)		 Cognitive Impairment, Sleep Quality
Related terms Cognitive Dysfunction, Sleep Initiation and Maintenance Disorders
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov